The effect of intraperitoneal interleukin-2 on surgically induced endometriosis in rats.
OBJECTIVE
To evaluate the effect of interleukin-2 (IL-2) on an experimental model of endometriosis.


METHODS
Double blind and randomized experimental prospective placebo-controlled study. Experimental endometriosis was induced in 66 three-month-old female Wistar rats, by auto-transplanting fragments of endometrium to the peritoneum. After four weeks, the size of each implant was measured in millimeters by laparotomy (L2), and animals were randomly distributed for intraperitoneal administration of human-IL-2, rat-IL-2 or placebo. Four weeks later, the implants were measured (L3) and a second dose was given. After four weeks, endometriosis size was evaluated again (L4).


RESULTS
We found a reduction of experimental endometriosis at L3 that was only significant in IL-2 treated groups: 20.1% and 30.3% with human-IL-2 and rat-IL-2, respectively (p<0.001 with respect to L2 size), versus a non-significant reduction of 9.0% found in placebo group, but the differences were not statistically significant between groups. The decrease after a second dose (L4) was: 49.8%, 41.8% and 11.4% with human-IL-2, rat-IL-2 and placebo, respectively (p<0.001 in IL-2 groups versus L2 and L3, and p<0.05 in both groups versus placebo at L4).


CONCLUSIONS
Intraperitoneal administration of IL-2 reduces experimental endometriosis, and this effect is similar using rat-IL-2 or human IL-2 (non specie-specific effect).
Quereda
Francisco
F
Division of Gynecology, School of Medicine, Miguel Hernández University, Alicante, Spain. fj.quereda@umh.es
Bermejo
Rosa
R
Velasco
Irene
I
Campos
Adolfo
A
Acién
Pedro
P
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D007274:Injections, Intraperitoneal; D007376:Interleukin-2 / Q000008:administration & dosage*; D010532:Peritoneal Diseases / Q000188:drug therapy*; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar
D000970:Antineoplastic Agents; D007376:Interleukin-2